Gov­ern­ment pan­el of­fers strongest rec­om­men­da­tion for PrEP to pre­vent HIV

The US Pre­ven­tive Ser­vices Task Force (USP­STF) pub­lished its strongest rec­om­men­da­tion that clin­i­cians should pre­scribe pre-ex­po­sure pro­phy­lax­is (PrEP) with ef­fec­tive an­ti­retro­vi­ral ther­a­py to peo­ple at in­creased risk of HIV ac­qui­si­tion.

The rec­om­men­da­tions in JA­MA on Tues­day came as part of an up­date to a 2019 re­view, and USP­STF gave its bless­ing to oral PrEP, which is as­so­ci­at­ed with de­creased risk of ac­quir­ing HIV in­fec­tion com­pared with place­bo or no PrEP. USP­STF added that Gilead’s De­scovy was non-in­fe­ri­or to its Tru­va­da brand and that the in­jectable cabote­gravir (Vi­iV Health­care’s Apre­tude) re­duced the risk of HIV in­fec­tion com­pared with Tru­va­da in the pop­u­la­tions stud­ied.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER